In Reply I thank Herold et al for their thoughtful letter and their commitment to improving the drug development process for children with cancer. As a leader of an international collaborative childhood cancer research organization, in my experience—contrary to their conclusion—the process surrounding pediatric investigation plan approvals is delaying the onset of a number of pediatric phase 1 cancer trials. While it is fully appreciated that completed early-phase trials have been accepted in the past by the European Medicines Agency, it is likely the effect of regulatory uncertainty1 that leads a number of biopharmaceutical industry sponsors to delay the onset of pediatric clinical research until a pediatric investigation plan is approved.
Adamson PC. Too Few Medicines for Children With Cancer—Reply. JAMA Pediatr. 2014;168(6):583–584. doi:10.1001/jamapediatrics.2014.18
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: